Stockscreener 앱 받기
297.02
2.48%
-7.56
시장 영업 전:
294.99
-2.03
-0.68%
전일 마감가:
$304.58
열려 있는:
$304
하루 거래량:
684.34K
Relative Volume:
0.68
시가총액:
$7.43B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-32.39
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
+7.72%
1개월 성능:
+51.19%
6개월 성능:
+590.74%
1년 성능:
+289.48%
1일 변동 폭
$285.95
$305.49
1주일 범위
$266.51
$317.72
52주 변동 폭
$26.70
$317.72
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
297.02 | 7.62B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug - ts2.tech
Praxis Precision Medicines stock gets FDA boost as H.C. Wainwright maintains Buy - Investing.com Canada
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.4%Here's Why - MarketBeat
Praxis Precision (PRAX) Shares Drop Amid Market Movement - GuruFocus
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock - Investing.com India
Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide - Yahoo Finance
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target - ts2.tech
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
Praxis Precision Medicines Stock Pre-Market (+12%) : FDA Breakthrough Therapy Designation for Ulixacaltamide - Trefis
Praxis Precision Medicines Stock Surges: What Drives the Wave? - StocksToTrade
Why Praxis Precision Medicines Stock Popped Today - Finviz
Why Praxis Precision Medicines Stock Popped Today - The Motley Fool
Praxis Precision Medicines: An Unexpected Surge? - timothysykes.com
Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines Soars on FDA Breakthrough Therapy Des - GuruFocus
Why Is Praxis Precision Medicines Stock Soaring Monday?Praxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Praxis Precision (PRAX) Soars 14.7% on Market Uptick - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighTime to Buy? - MarketBeat
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation - Investing.com
Praxis Precision Medicines (PRAX) Surges on FDA Breakthrough Des - GuruFocus
Jefferies reiterates Buy rating on Praxis Precision Medicines stock, cites FDA breakthrough designation - Investing.com UK
Why did Praxis Precision stock surge 12% pre-market today? - MSN
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
PRAX Stock Gains as FDA Grants Breakthrough Therapy Status to Ul - GuruFocus
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? - Asianet Newsable
Praxis Precision Medicines stock soars after FDA grants Breakthrough status - Investing.com
Praxis Precision Medicines stock soars after FDA grants Breakthrough status By Investing.com - Investing.com South Africa
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide By Investing.com - Investing.com Nigeria
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide - Investing.com
PRAX Stock Rises 13% in Premarket Trading - GuruFocus
PRAX Receives FDA Breakthrough Therapy Designation for Ulixacalt - GuruFocus
Praxis Wins FDA Breakthrough Status for Ulixacaltamide - TipRanks
Praxis Precision Medicines Receives Breakthrough Therapy Designation from FDA for Ulixacaltamide in Essential Tremor Treatment - Quiver Quantitative
Praxis Precision Medicines Receives Breakthrough Therapy Designation - TradingView — Track All Markets
FDA fast-tracks potential new treatment for people with essential tremor - Stock Titan
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG - Investing.com
BTIG Raises Price Target for PRAX to $843, Maintains Buy Rating - GuruFocus
Nvidia, Tesla, DigitalBridge, Newmont, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines Earnings Notes - Trefis
FDA-Endorsed Elsunersen Trial Redesign Could Be A Game Changer For Praxis Precision Medicines (PRAX) - Sahm
Congress Asset Management Co. Makes New Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) price target increased by 38.02% to 410.52 - MSN
Praxis Precision Medicines stock hits 52-week high at 283.04 USD - Investing.com Nigeria
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week HighWhat's Next? - MarketBeat
Medical Stocks To Follow NowDecember 5th - MarketBeat
Aug Wrap: Why Praxis Precision Medicines Inc. stock could be next big winnerMarket Risk Analysis & Fast Entry High Yield Tips - Улправда
Praxis Precision Medicines (PRAX) Price Target Increased by 38.02% to 410.52 - Nasdaq
Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.08%
자본화:
|
볼륨(24시간):